Woodline Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Woodline Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-234,736	Closed	-$20.3M	–	605
2023 Q2	$20.3M	Buy	234,736 +150,013	+177%	+$14.1M	0.24%	123
2023 Q1	$8.24M	Buy	+84,723	New	+$8.78M	0.11%	224
2022 Q4	–	Sell	-204,693	Closed	-$17.4M	–	762
2022 Q3	$17.4M	Sell	204,693 -198,476	-49%	-$17.7M	0.24%	121
2022 Q2	$33.4M	Buy	+403,169	New	+$32.1M	0.51%	39
2022 Q1	–	Sell	-447,654	Closed	-$39.5M	–	732
2021 Q4	$39.5M	Buy	+447,654	New	+$36.9M	0.57%	39
2020 Q2	–	Sell	-134,149	Closed	-$11.3M	–	155
2020 Q1	$11.3M	Sell	134,149 -23,558	-15%	-$2.03M	0.81%	38
2019 Q4	$13.3M	Buy	+157,707	New	+$11.9M	0.54%	60

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Woodline Partners's BMRN Position: Q3 2023 in Review

Woodline Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 234,736 shares — an estimated $20.3M sold.

Woodline Partners first reported a position in BMRN in Q4 2019 and held it in 7 quarters. The position peaked at $39.5M in Q4 2021. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Woodline Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Woodline Partners sold 234,736 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $20.3M.
Woodline Partners first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 7 quarters.
Woodline Partners's BioMarin Pharmaceuticals position peaked at $39.5M in Q4 2021.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Woodline Partners's 13F filing for Q3 2023, filed 14 Nov 2023.